Adel Samson

1.2k total citations
30 papers, 422 citations indexed

About

Adel Samson is a scholar working on Oncology, Genetics and Immunology. According to data from OpenAlex, Adel Samson has authored 30 papers receiving a total of 422 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 16 papers in Genetics and 11 papers in Immunology. Recurrent topics in Adel Samson's work include Virus-based gene therapy research (16 papers), CAR-T cell therapy research (16 papers) and Cancer Research and Treatments (10 papers). Adel Samson is often cited by papers focused on Virus-based gene therapy research (16 papers), CAR-T cell therapy research (16 papers) and Cancer Research and Treatments (10 papers). Adel Samson collaborates with scholars based in United Kingdom, United States and France. Adel Samson's co-authors include Alan Melcher, Kevin J. Harrington, Andrew F. Irvine, Rebecca Jones, Karen J. Scott, Richard G. Vile, Elizabeth Appleton, Fiona Errington‐Mais, Peter J. Selby and Hardev Pandha and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Adel Samson

29 papers receiving 417 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Adel Samson United Kingdom	12	244	164	155	135	52	30	422
Tyler Walther United States	3	317 1.3×	124 0.8×	116 0.7×	199 1.5×	82 1.6×	4	473
Javier Larrache Spain	6	170 0.7×	167 1.0×	151 1.0×	133 1.0×	20 0.4×	8	395
Derek Clouthier Canada	12	218 0.9×	95 0.6×	121 0.8×	336 2.5×	80 1.5×	20	541
Uxua Mancheño Spain	14	343 1.4×	164 1.0×	192 1.2×	350 2.6×	26 0.5×	19	623
Arnold Kloos Germany	14	408 1.7×	276 1.7×	220 1.4×	241 1.8×	43 0.8×	27	630
Bo Luan United States	7	302 1.2×	69 0.4×	251 1.6×	142 1.1×	49 0.9×	8	540
Miao-La Ke China	10	266 1.1×	48 0.3×	145 0.9×	249 1.8×	28 0.5×	11	476
Aygul Valiullina Russia	10	259 1.1×	69 0.4×	170 1.1×	148 1.1×	23 0.4×	17	412
Degui Geng United States	9	308 1.3×	84 0.5×	139 0.9×	321 2.4×	48 0.9×	14	565
Linda Hagerman Canada	8	221 0.9×	72 0.4×	124 0.8×	130 1.0×	21 0.4×	16	347

Countries citing papers authored by Adel Samson

Since Specialization

Citations

This map shows the geographic impact of Adel Samson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adel Samson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adel Samson more than expected).

Fields of papers citing papers by Adel Samson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adel Samson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adel Samson. The network helps show where Adel Samson may publish in the future.

Co-authorship network of co-authors of Adel Samson

This figure shows the co-authorship network connecting the top 25 collaborators of Adel Samson. A scholar is included among the top collaborators of Adel Samson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adel Samson. Adel Samson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Samson, Adel, et al.. (2024). Case report: Successful treatment of a patient undergoing haemodialysis with multifocal hepatocellular carcinoma using atezolizumab and bevacizumab. Frontiers in Oncology. 13. 1279501–1279501.

Davar, Diwakar, Benedito A. Carneiro, Grace K. Dy, et al.. (2024). Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV–GM-CSF), administered systemically in combination with durvalumab in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer. 12(11). e009336–e009336. 9 indexed citations

Patterson, Molly R., James A. Scarth, Christopher W. Wasson, et al.. (2024). E7-mediated repression of miR-203 promotes LASP1-dependent proliferation in HPV-positive cervical cancer. Oncogene. 43(28). 2184–2198. 3 indexed citations

Wong, Michael K., Joseph J. Sacco, Caroline Robert, et al.. (2024). Efficacy and safety of RP1 combined with nivolumab in patients with anti–PD-1–failed melanoma from the IGNYTE clinical trial.. Journal of Clinical Oncology. 42(16_suppl). 9517–9517. 11 indexed citations

Milhem, Mohammed, Judith Michels, Eva Muñoz‐Couselo, et al.. (2024). LBA46 Primary efficacy, safety, and survival data from the registration-intended cohort of patients with anti–PD-1–failed melanoma from the IGNYTE clinical trial with RP1 combined with nivolumab. Annals of Oncology. 35. S1236–S1237. 6 indexed citations

Samson, Adel, et al.. (2023). Combination treatment of HCC with SBRT and immune checkpoint inhibition. Critical Reviews in Oncology/Hematology. 192. 104191–104191. 4 indexed citations

Blackhall, Fiona, Adel Samson, K. Franks, et al.. (2023). 1502TiP A phase I/IIa trial of ChAdOx1 and MVA vaccines against MAGE-A3 and NY-ESO-1. Annals of Oncology. 34. S846–S846. 3 indexed citations

Scarth, James A., Christopher W. Wasson, Molly R. Patterson, et al.. (2023). Exploitation of ATP-sensitive potassium ion (KATP) channels by HPV promotes cervical cancer cell proliferation by contributing to MAPK/AP-1 signalling. Oncogene. 42(34). 2558–2577. 14 indexed citations

Samson, Adel, Cristina Smolenschi, Philippe A. Cassier, et al.. (2023). Abstract CT190: Oncolytic virus TG6002 safety and activity after intrahepatic artery administration in patients with liver-dominant metastatic colorectal cancer. Cancer Research. 83(8_Supplement). CT190–CT190. 1 indexed citations

10.

Short, Susan, et al.. (2022). Abstract CT569: Combination of reovirus (pelareorep) and granulocyte-macrophage colony-stimulating factor (GM-CSF) alongside standard chemoradiotherapy and adjuvant chemotherapy (temozolomide) for patients with glioblastoma multiforme (GBM): Long term follow up results of the ReoGlio phase Ib trial. Cancer Research. 82(12_Supplement). CT569–CT569. 3 indexed citations

11.

Schuelke, Matthew, Justin H. Gundelach, Matt Coffey, et al.. (2022). Phase I trial of sargramostim/pelareorep therapy in pediatric patients with recurrent or refractory high-grade brain tumors. Neuro-Oncology Advances. 4(1). vdac085–vdac085. 20 indexed citations

12.

Milhem, Mohammed, Ari M. Vanderwalde, Tawnya L. Bowles, et al.. (2022). Updated results from the skin cancer cohorts from an ongoing phase 1/2 multicohort study of RP1, an enhanced potency oncolytic HSV, combined with nivolumab (IGNYTE).. Journal of Clinical Oncology. 40(16_suppl). 9553–9553. 13 indexed citations

13.

West, Emma J., Karen J. Scott, Kaïdre Bendjama, et al.. (2022). Intravenous Oncolytic Vaccinia Virus Therapy Results in a Differential Immune Response between Cancer Patients. Cancers. 14(9). 2181–2181. 8 indexed citations

14.

Short, Susan, Emma J. West, Catherine McBain, et al.. (2022). P11.64.A Long-term follow up and translational data from the ReoGlio phase Ib trial of GM-CSF and intravenous pelareorep (Reovirus) alongside standard of care in GBM. Neuro-Oncology. 24(Supplement_2). ii73–ii73. 2 indexed citations

15.

Migneco, G, Gina B. Scott, Jenny Down, et al.. (2021). Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche. Journal for ImmunoTherapy of Cancer. 9(3). e001803–e001803. 14 indexed citations

16.

Appleton, Elizabeth, Charleen Chan Wah Hak, Anna Wilkins, et al.. (2021). Kickstarting Immunity in Cold Tumours: Localised Tumour Therapy Combinations With Immune Checkpoint Blockade. Frontiers in Immunology. 12. 754436–754436. 41 indexed citations

17.

Driscoll, Christopher B., Matthew Schuelke, Timothy Kottke, et al.. (2020). APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapy. Nature Communications. 11(1). 790–790. 49 indexed citations

18.

Middleton, Mark R., Francesca Aroldi, Joseph J. Sacco, et al.. (2020). An open-label, single-arm, phase II clinical trial of RP1, an enhanced potency oncolytic herpes virus, combined with nivolumab in four solid tumor types: Initial results from the skin cancer cohorts.. Journal of Clinical Oncology. 38(15_suppl). e22050–e22050. 16 indexed citations

19.

Jennings, Victoria A., Gina B. Scott, Karen J. Scott, et al.. (2019). Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition. Molecular Therapy. 27(6). 1139–1152. 47 indexed citations

20.

Samson, Adel, Matthew Bentham, Karen J. Scott, et al.. (2016). Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer. Gut. 67(3). 562–573. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact